EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Peptide-Derived Protease-Activated Receptor-1 (PAR-1) Antagonists

Steven M Seiler, Michael S Bernatowicz

Current Medicinal Chemistry-Cardiovascular & Hematological Agents · 2003

DOI: 10.2174/1568016033356689 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Medicinal Chemistry-Cardiovascular & Hematological Agents, 2003. Verfasst von Steven M Seiler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Biology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08534, USA. steven.seiler@bms.com. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protease activated receptor-1 (PAR-1) is a G-coupled receptor cleaved by thrombin and other proteases to expose a new N-terminus, a "tethered ligand", that activates the receptor. Independently of proteolytic cleavage, peptides similar to the new N-terminus also activate the receptor, and structure activity relationships for the activating peptides have been extensively studied. Modification of activating peptides led to rationally designed peptide antagonists. The more potent peptide antagonists were N-terminal and 3-position modifications of the agonist peptides. The resulting PAR-1 antagonists have proved useful in pharmacological studies resolving the contribution of PAR-1 signaling mechanisms relative to other PARs in platelets, vascular endothelial and other cell types. High affinity peptide agonists and antagonists have been radiolabled and proven useful in binding assays. Screening of combinatorial libraries and compound collections using the radioligands have identified non-peptide antagonists of several different chemotypes. When the "thrombin receptor" (PAR-1) was first cloned and its mechanism of activation elucidated, there was great enthusiasm for the receptor as a drug target. The use of peptide agonists and antagonists has made possible much progress in our understanding of the role of this receptor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsDrug DesignHumansInhibitory Concentration 50Molecular MimicryPeptidesReceptor, PAR-1Structure-Activity Relationship

Substanzen

PeptidesPlatelet Aggregation InhibitorsReceptor, PAR-1

Autor:innen und Institutionen

  • Department of Vascular Biology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08534, USA. steven.seiler@bms.com

Zitieren

APA

Seiler, S. M., & Bernatowicz, M. S. (2003). Peptide-Derived Protease-Activated Receptor-1 (PAR-1) Antagonists. Current Medicinal Chemistry-Cardiovascular & Hematological Agents. https://doi.org/10.2174/1568016033356689

Vancouver

Seiler SM, Bernatowicz MS. Peptide-Derived Protease-Activated Receptor-1 (PAR-1) Antagonists. Current Medicinal Chemistry-Cardiovascular & Hematological Agents. 2003. doi:10.2174/1568016033356689

BibTeX
@article{Seiler2003,
  author = {Seiler, Steven M and Bernatowicz, Michael S},
  title = {Peptide-Derived Protease-Activated Receptor-1 (PAR-1) Antagonists},
  journal = {Current Medicinal Chemistry-Cardiovascular & Hematological Agents},
  year = {2003},
  doi = {10.2174/1568016033356689}
}
Kostenlos starten →